IonQ reaches 1,000 patents milestone with new quantum computing grants
HACKENSACK, NJ - Champions Oncology , Inc. (NASDAQ:CSBR) saw its stock jump 6.7% after reporting third-quarter earnings that significantly exceeded analyst estimates. The oncology research services provider posted strong revenue growth and swung to a profit, driven by its first major data licensing deal.
For the fiscal third quarter ended January 31, 2025, Champions Oncology reported earnings per share of $0.36, beating the analyst consensus of -$0.01 by $0.37. Revenue surged 42% YoY to $17 million, surpassing expectations of $12.93 million.
The company’s top-line growth was fueled by a 4% increase in its research services business and $4.5 million from data license revenue. Champions Oncology signed its first data licensing agreement worth up to $8 million during the quarter, marking a significant milestone in monetizing its proprietary data platform.
"Our third quarter was transformational, marked by our first major data licensing agreement-an important milestone toward monetizing our proprietary data platform," said CEO Ronnie Morris. "Despite ongoing funding constraints in the pharma and biotech sectors, we continue to drive strong performance in our core services business."
The company reported net income of approximately $4.5 million for the quarter, compared to a loss in the same period last year. Adjusted EBITDA reached $5.2 million, up from a loss of $1.7 million in the prior-year quarter.
Champions Oncology ended the quarter with $3.2 million in cash and no debt. While management anticipates some fluctuations in quarterly revenue, they believe recent cost realignment efforts position the company for sustained long-term profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.